The transaction involved an exercise of 10,983 stock options, which were immediately sold as shares on the open market. This ...

Highlights from the 2025 Muscular Dystrophy Association (MDA) Conference include clinical updates, expert insights, and ...

New Delhi [India] / Dubai [UAE], December 31: As cases of chronic facial pain, jaw dysfunction and undiagnosed ...

Soraya Bekkali, Alexion SVP Europe, Canada and International region, discusses the realities patients with generalised Myasthenia Gravis face across Europe, and how modernised, evidence-based care ...

Tobi Jesse turned 4 years old on Christmas Eve. He lives with autism and a rare, progressive neuromuscular disease called ...

Grants include research funding in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), mitochondrial ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the ...

Inspired by his father, Grandview High School student Josue Clara started a nonprofit called Beyond Rare to build awareness ...

The Muscular Dystrophy Association (MDA) announced today that John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), will deliver the keynote address at the 2026 MDA ...

HHS has announced the addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Uniform ...

Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, ...